Fecal microbiota transplantation for membranous nephropathy
Related Experiment Video
Updated: Nov 23, 2025
Murine Fecal Isolation and Microbiota Transplantation
Published on: May 26, 2023
Guanzhou Zhou1,2, Jiaqi Zeng1,2, Lihua Peng1
1Department of Gastroenterology and Hepatology, The First Medical Center, Chinese PLA General Hospital, Beijing, 100853, China.
Abstract:
Membranous nephropathy is a pathological type of nephrotic syndrome. Current treatments including supportive therapy, corticosteroids, immunosuppressive agents are not effective for all patients. New therapies are needed to treat the disease safely and effectively. Gut microbiota may contribute to the pathogenesis of this disease. Fecal microbiota transplantation (FMT) has made achievements in many diseases. Here, we report a case in which FMT is used to treat a patient with membranous nephropathy and chronic diarrhea, whose symptoms ameliorated and renal function improved.
Insights
Fecal microbiota transplantation (FMT) shows promise for treating membranous nephropathy and chronic diarrhea. This innovative therapy improved patient symptoms and enhanced kidney function, offering a new therapeutic avenue.
Area of Science:
- Nephrology
- Gastroenterology
- Microbiology
Background:
- Membranous nephropathy, a cause of nephrotic syndrome, has limited treatment options.
- Current therapies like corticosteroids and immunosuppressants are not universally effective.
- Gut microbiota's role in membranous nephropathy pathogenesis is increasingly recognized.
